From the erlotinib study [47], we can speculate that Compound 12 might enhance the effects of gefitinib not only by inhibiting HIF-1α synthesis, but also by inducing vascular normalization, resulting in improved vascular delivery of gefitinib to the tumor tissues. Here, HIF1A is linked to neoplasm.